16:51 23 March 2026
Pharmena establishes Synerixa platform to focus on development of local products
Pharmena has launched a new R&D platform, Synerixa, focused on developing innovative topical products. The platform enables parallel development of multiple projects at different stages and supports building a scalable portfolio in selected medical and specialist areas.
Currently, two main projects are underway. The first targets hard-to-heal wounds, with a medical device in the biocompatibility testing phase and clinical trials planned, followed by EU certification around 2027. The second project focuses on psoriasis, where patient studies have been completed and further commercialization options are being assessed.
Synerixa aligns with Pharmena’s strategy of leveraging the potential of its 1-MNA molecule and expanding into complementary areas such as healthy ageing and drug discovery.
